The five-year survival rate for many cancers has significantly increased, finds a new report from the American Cancer Society.
Specifically, people are living longer with some of the more deadly cancers, including lung, liver and myeloma — cancer of plasma cells. Scientists estimate a combined increase in five-year survival for all cancers at 70%.
“Seven in 10 people now survive their cancer five years or more, up from only half in the mid-70s,” said Rebecca Siegel, senior scientific director of surveillance research at the American Cancer Society and lead author of the report, in a Jan. 13 news release.
Scientists attribute the improvements to earlier detection and diagnosis, better treatment and a decline in smoking. Lung cancer survival, for example, increased since the mid-1990s, from 20% to 37%.
Pittsburgh cancer experts lauded the news as a step in the right direction for cancer treatment and patient outcomes, but said rates could be better. Although the American Cancer Society (ACS) estimated improvements to have averted nearly 5 million cancer deaths in the U.S. over 35 years, 626,000 Americans are expected to die from the disease this year.
“People should be excited to hear the dramatic improvements that have occurred,” said Stanley Marks, chairman of UPMC Hillman Cancer Center and a medical oncologist. “At the same time, they could be better. Many of these cancers are now becoming chronic diseases.”
Read More
Pennsylvania’s survival rate for lung cancer has improved over time, though more people in the commonwealth smoke compared to the national average. Rates are worse in the neighboring states of West Virginia and Ohio: In 2022, for instance, West Virginia led the country in smoking rates at one in five adults, or 20%; Ohio was at 17%, Pennsylvania at 15%, per the American Lung Assocation.
Lung and bronchus cancers are estimated to be the leading cause of cancer death in 2026, according to the ACS report.
Researchers at ACS pulled data from a variety of cancer incidence registries, which states report to the Centers for Disease Control and Prevention. Mortality data was gathered from the National Center for Health Statistics.
While ACS has been publishing the cancer statistics report since 1951, this is the first time the report has shown such a notable increase in cancer survival, the agency said in its news release. Siegel called it a “stunning victory.”

A drop in smoking rates has certainly impacted the statistics, said Marks.
“Pittsburgh has a high incidence of many cancers, including lung, and it has a heavy smoking population and pollution, and a high aging population,” he said.
On the other hand, Marks pointed to the Hillman Cancer Center as a stalwart, being the only National Cancer Institute-designated center in the region — it’s one of 73 national centers that receives funding and support directly from NCI.
Allegheny Health Network has also made gains, offering free cancer screenings at hospitals across Western Pennsylvania for four years and working on a blood test for cancers, partnering with biotech monoliths including Illumina.
“We have to improve our technology around cancer screening,” said David Bartlett, chair of the AHN Cancer Institute. “Blood test technology will continue to improve, and I think this will be a reality.”
Scientists, though, warn that gains may be fragile as billions of federal dollars for research were cut in 2025 and Americans lost access to health care coverage when Medicaid extensions lapsed.
More than 3,800 research grants and $2.3 billion in funding were cut last year, including millions for cancer research, found a Science News analysis.
Health Secretary Robert F. Kennedy Jr. also cut $500 million in funding for mRNA vaccine technology, which scientists were exploring as a potential for a cancer vaccine. A recent report from the Yale School of Public Health found that advances in mRNA vaccine technology could avert 49,000 preventable cancer deaths annually.
“Our analysis shows that mRNA cancer vaccines have the potential to save tens of thousands of lives and generate enormous economic value in the United States,” said Alison Galvani, founding director of the Yale Center for Infectious Disease Modeling and Analysis and an epidemiology professor at Yale, in a news release about the report.
“Abandoning this technology risks forfeiting one of the most promising advances in cancer treatment in decades,” she said.
This includes cuts to Pittsburgh’s cancer research institutions.
“We’re very concerned,” said Marks, of UPMC. “These funding cuts to our research programs can only be detrimental to our research efforts and patient outcomes.”
There’s no question that federal funding is critical for the discovery and development of new cancer drugs and screening tools, said Bartlett.
“When you talk about 626,000 deaths from this disease in the U.S., it’s certainly worthy of the investment.”





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.